A Review on New Developments in Vaccinology

Shital U. Adhao[1], Manali M. Bode[2], Harigopal S. Sawarkar[3]

[1]Student, [2]Assistant Professor, [3]Principal
Dr. Rajendra Gode College of Pharmacy, Amravati, Maharashtra

Abstract

The most economical, secure, and effective medical intervention for preventing infectious disease-related illnesses, disabilities, and fatalities is still vaccination. When the traditional vaccines were created, little was known about the mechanisms underlying immunity and the causes of diseases. The majority of vaccines were created through trial and error in both human and animal studies. Recent developments in immunology, molecular biology, and recombinant DNA technology have made it possible to comprehend how antigens are interpreted and delivered to the immune system and how this influences the immune response. Additionally, studies into the mechanism by which pathogens infect and cause disease are currently being conducted. An exciting field in the prevention and control of infectious diseases is promised by the advancements in vaccine technology, including DNA vaccines, transgenic plant vaccines, and vaccine combinations.

Keywords: Vaccinology, Immunomodulator, DNA, Bacterial toxins

Introduction

Developments in the field of vaccination have had a significant impact on the emergence and prevention of numerous infectious diseases[1]. Biological preparations called vaccines are used to create active immunity, which makes the immune system create immunological memory against disease parameters. Numerous microbial agents have been managed and eliminated globally as a result of the effective use of vaccines against various infections. Among interventions for infectious diseases, vaccines are crucial for managing infectious diseases. By attaining an 80% decrease in disease incidence, 13 infections have been managed globally over the years through the use of vaccines either alone or in conjunction with other control measures. While some diseases have been virtually eradicated, others are primarily controlled in specific geographic areas[2]. Childhood vaccinations prevent between 2 to 3 million deaths annually worldwide, according to estimates from the World Health Organisation [3]. Without question, vaccines have been a successful medical intervention in reducing disease and enhancing world health. Since Edward Jenner's groundbreaking work on the smallpox vaccine two centuries ago, smallpox has been successfully eradicated thanks to successful immunisation campaigns and gradual vaccine improvements. The anti-polio vaccine has been another of modern medicine's great success stories; the disease has been successfully eradicated in the majority of the world, and with so few new cases reported in the first few months of 2017, the eradication of poliomyelitis appears to be achievable on a global scale [4]. The tremendous cost of polio eradication initiatives, together with logistical, scientific, and cultural obstacles, may, however, dampen interest in attempts to eradicate other infectious illnesses while keeping control as the primary objective. The list of vaccine-preventable illnesses (VPDs) is growing, however, and current vaccines can be enhanced to improve tolerability and lengthen protection[5].

History

In the seventh century, some Indian Buddhists tried to become immune to the effects of snake venom by drinking it. Toxoid-like immunity might have been induced by them (Plotkin&Plotkin, 1999). Early in the eighteenth century, the Chinese practice of variolation—which involves inoculating smallpox patients' pus to prevent the disease naturally—was brought to Europe.

With his methodical and successful attempt to eradicate smallpox in 1796, Edward Jenner set the first vaccination milestone. Then.

The attenuation process was discovered by Louis Pasteur when he unintentionally noticed that chicken Cholera bacillus cultures kept their capacity to shield birds from further infection after two weeks on the bench and lost their pathogenicity (Pasteur, 1880) which resulted in the development of live vaccines and the identification of the attenuation process.

He successfully created the first rabies vaccine in 1885, which offers immunity against the illness by injecting the body with attenuated germs (virus). One of the pioneers in the field of vaccineology, Louis Pasteur is credited with giving these preventative preparations the name "Vaccine."

Calmette and Guerin repeatedly subcultured tubercle bacillus that Nocard had initially isolated from a cow in order to create a stable and attenuated strain of Mycobacterium bovis against tuberculosis in 1902. A significant change in the process for creating safe vaccines was signalled by the introduction of inactivated vaccine in 1890. Early in the 20th century, a variety of bacterial and viral vaccine preparations were released that contained either whole-inactivated bacteria, viruses, or semi-purified detoxified bacterial toxins [6,7].

New Developments

1) DNA Vaccines and immunostimulator

DNA vaccines differ from conventional vaccinations in that they typically contain plasmids, which are tiny rings of double-stranded DNA generated from bacteria (such as Escherichia coli) that are incapable of causing infection. Plasmids containing one or more genes extracted from disease-causing pathogens are then injected into muscle using a gene gun or injection. Proteins (antigens) that trigger humour and cellular immunity are expressed by the foreign genes. Immunologists were thrilled about DNA's capacity to trigger a wide range of immunological responses, including humoral immunity (antibodies) and cell-mediated immunity, particularly cytotoxic T lymphocytes (CTL) [8].

It was found in 1996 that different plasmids had different capacities for eliciting immune responses after DNA vaccination. The presence of distinct antibiotic markers caused plasmids with the same cDNA and the same promoter to elicit radically different immune responses [9]. Immunostimulatory sequences (ISSs) are unmethylatedCpG motifs found in the plasmid that were found to be the cause. Mammalian cells seemed capable of identifying bacterial DNA and launching an inflammatory reaction in response.

Interest in ISS DNA exists for both its incorporation into DNA vaccines and its use as an adjuvant in traditional protein vaccinations [10,11].Over the past few years, a series of mammalian homologues for Drosophila Toll protein have been identified [12,13].As pattern-recognition receptors, it has become clear that these Toll-like receptors (TLRs) play significant roles in innate immunity. Specifically, TLR2 seems to be crucial for identifying components of Gram-positive cell walls, and TLR4 is involved in lipopolysaccharide (LPS) responses and respiratory syncytial virus binding [14,15].TLR9, a new receptor, was recently discovered to be the receptor for bacterial CpG motifs based on sequence homology with other TLRs [16].TLR9 knockout mice's cells do not multiply or release cytokines in reaction to CpG DNA. Clarifying the mechanism of action of ISSs is a positive step that could undoubtedly result in better immunostimulatory sequences. Nevertheless, any benefit of using ISSs as adjuvants over bacterial cell wall components will primarily depend on the different TLR expression and signalling patterns, which are still being ascertained [17].

Benefits of DNA vaccinations:

1 Risk-free and disease-free

2 Wide-ranging immune reaction

3 Normal antigen confirmation

4 No reaction at the injection site

5 Long immunity duration

6 Easy and inexpensive production

7 It is possible to administer several vaccines at once.

8 Possible neonatal vaccination in the presence of maternal antibody

9 A range of delivery options are available

2) Prime boost —an emerging strategy for immunisation

DNA immunisation frequently fails to elicit a robust immune response, and it is now acknowledged that a so-called heterologous prime-boost strategy is one of the most effective means of producing a robust cellular response in particular. Priming in these situations typically involves a DNA vaccine that is enhanced by purified protein or a recombinant viral vector like adenovirus or vaccinia. Some of the advancements listed below have been made possible by prime-boost strategies, which Schneider et al. Have reviewed [18].

3) mRNA Vaccines

A novel class of vaccines known as mRNA vaccines uses the machinery of the cell to produce particular proteins required to combat illness. They are currently being evaluated for a pneumonic plague outbreak after being effectively employed for COVID-19. Licenses have been granted to Moderna and BioNTech for their mRNA vaccines, mRNA-1273 and BNT162b2, respectively. BioNTech's vaccine has a full licence, whereas Moderna's has a conditional licence. An adjuvant has been added to the vaccine formulation to improve stability and efficacy. Research, development, and production of these vaccines have advanced quickly because to funding and investments. Although they may be impacted by virus changes, both vaccines have demonstrated efficacy against COVID-19 and require two doses. The businesses have put in place logistical safeguards to guarantee the integrity of the vaccines while they are being transported. These vaccines show off the advantages and possibilities of mRNA-based vaccinations [19].

4) Cancer vaccines —moving toward the clinic

Standard therapies against metastatic renal cell carcinoma achieve responses in fewer than 10% of cases. Kugler et al. [20] recently reported a clinical trial that used immunisation with tumour cells fused to allogeneic dendritic cells.In this trial, seven out of 17 patients responded, and fourOut of 17 patients achieved complete regression of tumoursWith no recurrence over a 21-month follow-up period. One of the advantages of such an approach is, of course, that the tumour antigens do not need to be identified, although in this case the authors did identify an enhanced CTLResponse against the Muc-1 antigen, which is overexpresseon a range ofcarcinomas.

5) Alzheimer's disease

The 42 amino acid form of the amyloid beta protein (Aβ42) makes up the majority of the amyloid plaques associated with Alzheimer's disease. Amyloid precursor protein (APP) and presenilin gene mutations are linked to increased Aβ42 production in Alzheimer's patients. Transgenic PDAPP mice exhibit immunopathology resembling Alzheimer's disease when they express a mutant form of human APP. Schenk et al.[21]administered Aβ42 in Freund's adjuvant to these mice either before or after neuropathology developed. Immunisation mitigated the severity of the pathology and its progression in the older mice while preventing the development of neuropathology in the younger mice. Using various transgenic models, other studies [22,23] have demonstrated that Aβ42 immunisation also enhanced behavioural outcomes in the mice by enhancing learning capacity and lowering memory loss.

6) Stroke

Neuronal cell death after stroke, epileptic seizures, and trauma is linked to the N-methyl-D-aspartate (NMDA) receptor for glutamate. Although they are being studied, pharmacological antagonists typically have a low therapeutic ratio. The brain is normally considered an immunologically privileged site, with the 'blood−brain barrier' relatively impenetrable to antibodies. During et al. [24] tried to use this brain characteristic to create a preventative vaccine against stroke-related damage. According to the authors, unless there was damage, in which case the autoantibodies could enter the brain and have protective effects, the blood–brain barrier would mitigate any adverse effects of anti-NMDA-receptor antibodies. An adeno-associated virus that expressed the ubiquitous NMDA receptor subunit NR1 immunised them. In

experimental models of epilepsy and stroke, oral immunisation produced antibody responses against NMDA receptors but no discernible T-cell responses.

Preclinical and Clinical trial advances:

The focus of HIV vaccine research is shifting more and more towards efforts to elicit potent anti-virus cytotoxic T lymphocyte (CTL) responses[25].DNA vaccination is becoming a more common way to accomplish this goal. Chimeric SHIV (simian immunodeficiency virus with surface glycoproteins from HIV) has been shown in two recent studies to protect macaques against AIDS after DNA vaccination. Robinson et al.[26]employed eight distinct prime-boost regimes in total. The most successful combination was an intradermal DNA vaccination followed by boosts with a recombinant fowlpox virus that expressed SHIV proteins. This provided protection against three challenge infections, with a heterologous virus serving as the last challenge. Neutralising antibodies were not necessary for disease protection, but they also didn't seem to be related to CTL activity. The authors hypothesised that protection could be provided by non-cytolytic CD8 activity [27]. [28] Barouch et al. Additionally employed DNA vaccination in the absence of a protein boost.In this instance, adding an interleukin-2-Ig fusion protein or a plasmid encoding that protein to the vaccination significantly increased the CTL response brought on by the DNA vaccine (see also Update). In this instance, it did seem that CTL responses were associated with protection against clinical disease. It was also demonstrated that a prime-boost approach consisting of DNA vaccination and recombinant adenovirus produced 100% protection against the Ebola virus [29], indicating the path towards a vaccine for humans against this horrifying illness.

Boyle et al. [30] and Deliyannis et al. [31] suggested another way to boost responses against DNA vaccination. They demonstrated that vaccines encoding CTLA4-antigen fusions could significantly boost the immune response against the antigen by directing the antigen to antigen-presenting cells (APCs).

Even though co-injection of different cytokine-encoding plasmids to improve DNA vaccination has been reported many times, the goal is typically not to trigger an immune response against the cytokine. Using a model of adjuvant-induced rheumatoid arthritis, Wildbaum et al. [32] discovered that pre-immunization with a plasmid encoding tumour necrosis factor α (TNFα)prevented arthritis by triggering the production of anti-TNF autoantibody memory. Anti-TNF antibodies were only produced when autoimmune arthritis was induced, not during a typical delayed-type hypersensitivity reaction. Most significantly, the vaccine may be used therapeutically to induce long-term remission of arthritis after it has started.

Influenza virus infection triggers antibody responses that are primarily focused on the two viral glycoproteins, neuraminidase (NA) and haemagglutinin (HA).

Unfortunately, antigenic drift and shift cause these proteins to vary greatly. Therefore, HA and NA vaccination only partially or not at all protects against heterologous virus strains. A different strategy that makes use of a segment of the M2 (matrix) protein has been effectively shown to be effective by Neirynck et al. [33].

Although the majority of this protein is intracellular, the viral membrane also contains it, and the surface of infected cells contains 24 amino acids. Fusions between this protein and the hepatitis B core antigen were created by the authors. Mice that were immunised showed protection against a wide range of virus serotypes. Intranasal vaccination was one way to induce the primarily antibody-mediated protection. It is unclear whether vaccination with the M2 protein will result in the evolution of variants (escape mutants) to which the antibody does not bind because, of course, the vaccine generated a far stronger antibody response against the protein than is typically observed after infection.

Following the discovery of a carbohydrate antigen that is not frequently observed on S. Aureus strains in vitro but is expressed on the cell surface during infection, a broadly protective vaccine against S. Aureus was also shown. Mice were immunised with poly-N-succinyl-B 1,6 glucosamine (PNSG), which offered defence against a variety of S. Aureus strains, including those that did not express PNSG in vitro [34].

LaCasse et al. [35] adopted a similar strategy with the goal of HIV vaccination. Only the gp120−CD4 complex is recognised by certain monoclonal antibodies; neither component is recognised by them alone. Because of this, these epitopes are absent from the majority of vaccine antigens used in HIV vaccination that have produced neutralising antibodies, though typically not against heterologous primary isolates.

During the fusion process, LaCasse et al. Combined cells that expressed the viral envelope protein with cells that expressed CD4 and the chemokine receptor CCR5, and they fixed the mixtures five hours later. These

fixed cells were used to immunise mice; however, hCD4/hCCR5 transgenic mice were employed to rule out any anti-CD4 or anti-CCR5 activity that might be neutralising.The generated antisera exhibited broad neutralising activity against the virus's primary isolates. It ought to be feasible to produce vaccine antigens that closely.

Challenges in Vaccinology

• High (and increasing) costs for vaccine development (~$700 million–$1 billion)
• Vaccine hesitancy
• More stringent safety requirements
• Societal expectations of 100% efficacy
• Need to maintain cold-chain for vaccines
• Increasing requirements for single dose efficacy
• Need for rapid response to global outbreaks
• Limited number of vaccine manufacturers
• Product development time (typically ~10 years)
• Current pathogens require more complicated vaccines
• Inadequate durability of immune response (ex. Pertussis)
• Humoral immune responses do not always correlate with protection
• Limited number of approved and acceptable adjuvants

Conclusion:

Numerous new vaccines for young children will be added as a result of the current surge in vaccine research, which is backed by immunology, molecular biology, biochemistry, and related fields. There were vaccines available against 15 infectious diseases in humans in 1960, but by 1998, there were 37. These days, it is also widely understood how the immune system processes and presents antigens, as well as how this influences immune responses. Additionally, research is being done to determine how pathogens infect people and cause illnesses. Over 500 potential vaccines are currently being developed. The concepts of vaccination are being expanded to include conditions like diabetes, peanut allergies, gastric ulcers, cervical cancer, blindness, and coronary artery diseases. Nonetheless, research on HIV, TB, and malaria over the last 15 years has demonstrated the importance of advances in other fields, and scientists are hopeful that new vaccines will be developed to combat these threats.

References:

1. World Health Organisation expanded programme on immunization:Polio eradication campaign. [See URL:http://www.polioeradication.org].
2. Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards Elimination goals for viral hepatitis. Nature reviews Gastroenterology &hepatology. 2020 Sep;17(9):533-42. Nature.com
3. World Health Organization, Global Immunization Vision and Strat-Egy 2006–2015 2016. Availableat:http://www.who.int/mediacentre/Factsheets/fs378/en/
4. Polio Global Eradication Initiative, Polio today. 2017. Available at:http://polioeradication.org/polio-today/polio-now/this-week/
5. World Health Organization, Immunization Highlights 2013. 2014.Availableat:http://www.euro.who.int/__data/assets/pdf_file/0007/248236/Immunization-Highlights-2013-E.pdf
6. Calmette A et at, 1924. Essaisd'immunizationcontrelinfectionTuberculeuse. Bull Acad Med, 91, 787. In New GenerationVaccines, edited by Levine M M et at, 2NdEdition, MarcelDekker Inc, New York, 1-11.
7. Plotkin S L &Plotkin S A, 1999. A short history of vaccinations.In Vaccine, edited by S L Plotkin and
8. Donnelly J J et at, 1997. Further protection against antigenic drift Of influenza virus in a ferret model by DNA vaccination.Vaccine, 15, 865-868.

9. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ,Lotz M, Carson DA, Raz E: Immunostimulatory DNA sequencesNecessary for effective intradermal gene immunization. Science 1996, 273:352-354.
10. Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J,Richman DD, Eiden JJ, Spiegelberg HL, Raz E: Conjugation ofProtein to immunostimulatory DNA results in a rapid, long-lastingAnd potent induction of cell-mediated and humoral immunity. EurJ Immunol 2000, 30:1939-1947.
11. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E: Immunostimulatory DNA-based vaccines induce cytotoxic Lymphocyte activity by a T helper cell-independent mechanism.NatBiotechnol 2000, 18:509-514.
12. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. RuslanMedzhitov, Paula Preston-Hurlburt, Charles A. Janeway (1997). Nature.
13. A family of human receptors structurally related to Drosophila Toll. Fernando L. Rock, Gary Hardiman, Jackie C. Timans, Robert A. Kastelein, J. Fernando Bazan (1998). Proceedings of the National Academy of Sciences.
14. Toll-like receptors in the induction of the innate immune response. Alan Aderem, Richard J. Ulevitch (2000). Nature.
15. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Evelyn A. Kurt-Jones, Lana Popova, Laura Kwinn, Lia M. Haynes, Les P. Jones, Ralph A. Tripp, Edward E. Walsh, Mason W. Freeman, Douglas T. Golenbock, Larry J. Anderson, Robert W. Finberg (2000). Nature Immunology.
16. A Toll-like receptor recognizes bacterial DNA. Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai, TsuneyasuKaisho, Shintaro Sato, Hideki Sanjo, Makoto Matsumoto, Katsuaki Hoshino, Hermann Wagner, Kiyoshi Takeda, Shizuo Akira (2000). Nature.
17. Toll-like receptors in innate immune recognition. RuslanMedzhitov (2001). Biochemical Society Transactions.
18. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Jörg Schneider, Sarah C. Gilbert, Carolyn M. Hannan, PilarDégano, Eric Prieur, Eric G. Sheu, Magdalena Plebanski, Adrian V. S. Hill (1999). Immunological Reviews.
19. COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. Jean-Marc Cavaillon, Marcin F. Osuchowski (2021). Journal of Intensive Medicine.
20. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids. Alexander Kugler, GernotStuhler, Peter Walden, Gerhard Zöller, AnkeZobywalski, Peter Brossart, Uwe Trefzer, SilkeUllrich, Claudia A. Müller, Volker Becker, Andreas J. Gross, Bernhard Hemmerlein, LotharKanz, Gerhard A. Müller, Rolf-Hermann Ringert (2000). Nature Medicine.
21. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Dale Schenk, Robin Barbour, Whitney Dunn, Grace Gordon, Henry Grajeda, Teresa Guido, Kang Hu, Jiping Huang, Kelly Johnson-Wood, Karen Khan, Dora Kholodenko, Mike Lee, Zhenmei Liao, Ivan Lieberburg, Ruth Motter, Linda Mutter, Ferdie Soriano, George Shopp, Nicki Vasquez, Christopher Vandevert, Shannan Walker, Mark Wogulis, Ted Yednock, Dora Games, Peter Seubert (1999). Nature.
22. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Christopher Janus, Jacqueline Pearson, JoAnne McLaurin, Paul M. Mathews, Ying Jiang, Stephen D. Schmidt, M. Azhar Chishti, Patrick Horne, Donna Heslin, Janet French, Howard T.J. Mount, Ralph A. Nixon, Marc Mercken, Catherine Bergeron, Paul E. Fraser, Peter St George-Hyslop, David Westaway (2000). Nature.
23. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Dave Morgan, David M. Diamond, Paul E. Gottschall, Kenneth E. Ugen, Chad Dickey, John Hardy, Karen Duff, Paul Jantzen, Giovanni DiCarlo, Donna Wilcock, Karen Connor, Jaime Hatcher, Caroline Hope, Marcia Gordon, Gary W. Arendash (2000). Nature.
24. An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy. Matthew J. During, Charles W. Symes, Patricia A. Lawlor, John Lin, Jane Dunning, Helen L. Fitzsimons, David Poulsen, Paola Leone, Ruian Xu, Bridget L. Dicker, Janusz Lipski, Deborah Young (2000). Science.
25. Is an HIV vaccine possible?. Andrew J. McMichael, Tomas Hanke (1999). Nature Medicine.

26. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Harriet L. Robinson, David C. Montefiori, R. Paul Johnson, Kelledy H. Manson, Marcia L. Kalish, Jeffrey D. Lifson, Tahir A. Rizvi, Shan Lu, Shiu-Lok Hu, Gail P. Mazzara, Dennis L. Panicali, James G. Herndon, Rhona Glickman, Maria A. Candido, Shari L. Lydy, Michael S. Wyand, Harold M. McClure (1999). Nature Medicine.
27. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Jay A. Levy, Carl E. Mackewicz, Edward Barker (1996). Immunology Today.
28. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. Science 2000;290:486–492. (2001). American Journal of Ophthalmology.
29. Development of a preventive vaccine for Ebola virus infection in primates. Nancy J. Sullivan, Anthony Sanchez, Pierre E. Rollin, Zhi-yong Yang, Gary J. Nabel (2000). Nature.
30. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. J. S. Boyle, J. L. Brady, A. M. Lew (1998). Nature.
31. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Georgia Deliyannis, Jefferey S. Boyle, Jamie L. Brady, Lorena E. Brown, Andrew M. Lew (2000). Proceedings of the National Academy of Sciences.
32. A Targeted DNA Vaccine Augments the Natural Immune Response to Self TNF-α and Suppresses Ongoing Adjuvant Arthritis. GiziWildbaum, Sawsan Youssef, Nathan Karin (2000). The Journal of Immunology.
33. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Sabine Neirynck, Tom Deroo, Xavier Saelens, Peter Vanlandschoot, Willy Min Jou, Walter Fiers (1999). Nature Medicine.
34. Broadly Protective Vaccine for Staphylococcus aureus Based on an in Vivo-Expressed Antigen. David McKenney, Kimberly L. Pouliot, Ying Wang, Vivek Murthy, Martina Ulrich, GerdDöring, Jean C. Lee, Donald A. Goldmann, Gerald B. Pier (1999). Science.
35. Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV. Rachel A. LaCasse, Kathryn E. Follis, Meg Trahey, John D. Scarborough, Dan R. Littman, Jack H. Nunberg (1999). Science.